REAL LIFE DATA FOR DYSPLASTIC BARRETT'S ESOPHAGUS MANAGEMENT AND FOLLOW-UP

2019 ◽  
Author(s):  
S Michopoulos ◽  
G Axiaris ◽  
P Baxevanis ◽  
M Stoupaki ◽  
V Gagari ◽  
...  
Keyword(s):  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

Mo1190 REAL LIFE DATA FOR DYSPLASTIC BARRETT’S ESOPHAGUS MANAGEMENT AND FOLLOW-UP

2019 ◽  
Vol 89 (6) ◽  
pp. AB456
Author(s):  
Spyridon Michopoulos ◽  
Georgios Axiaris ◽  
Panagiotis Baxevanis ◽  
Maria Stoupaki ◽  
Vasiliki Gagari ◽  
...  
Keyword(s):  
Barrett’S Esophagus ◽  
Barrett's Esophagus ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

Epidemiology and patterns of care of intrahepatic cholangiocarcinoma (iCCA) in France: Real-life data from the French National Hospital‐Discharge Summaries Database System (PMSI).

2020 ◽  
Vol 38 (15_suppl) ◽  
pp. e16624-e16624
Author(s):  
Cindy Neuzillet ◽  
Corinne Emery ◽  
Clément Teissier ◽  
Stéphane Bouée ◽  
Astrid Lièvre
Keyword(s):  
Intrahepatic Bile Duct ◽  
Real Life ◽  
High Volume ◽  
Cancer Registries ◽  
Best Supportive Care ◽  
Patterns Of Care ◽  
University Hospitals ◽  
Life Data ◽  
Real Life Data

e16624 Background: Little is known about epidemiology and patterns of care of iCCA in daily clinical practice. The aims of this study were to estimate from real-life data the incidence of iCCA in France and to describe the healthcare pathways of these patients (pts). Methods: A retrospective analysis was carried out using the nationwide prospective French PMSI database. All pts with a new diagnosis of "carcinoma of the intrahepatic bile duct" who had a 1st hospital stay in Medicine, Surgery and Obstetrics departments (MSO) between 2014 and 2015 with a 2-year follow-up were included. Data related to the 1st identified stay (S1) in MSO and on all subsequent stays in MSO, Aftercare and Rehabilitation (SSR) or Home Hospitalizations (HAD) were analyzed. Results: A total of 3,650 new iCCA cases were identified. At S1 (admission via emergency room [ER] in 28%), median age of pts was 73y, 57% were male and 35% had metastases. Jaundice/anemia/ascites/cholangitis were reported in 17%/16%/12%/7%, respectively. Pts care at S1 was mainly provided in general hospitals (CHG, 60%), rather than university hospitals (CHU, 15%), private (20%) or cancer centers (CLCC, 6%). 896 (24%) pts died during S1: they were more frequently hospitalized via ER (48% vs 23%), metastatic (52% vs 35%) and symptomatic. Subsequent stays were identified for 2,507 pts (69%). Similarly to S1, most pts were managed in CHG during their follow-up (70% vs 20% in CHU and 12% in CLCC). Based on the number of pts treated over the study period, centers were classified as low (≤5 pts, 68%), intermediate (5-20 pts, 26%) and high volume ( > 20 pts, 6%). 47% of the high-volume centers were CHU/CLCC. Three healthcare pathways were defined: surgery (n = 519; 14%), chemotherapy (CT) without surgery (n = 812; 22%) and best supportive care (BSC) (n = 2,319; 63%). CT, surgery and BSC were most frequently performed in CLCC, CHU and CHG, respectively. Pts who received CT (mean time between S1 and start of CT: 1.9 months) were younger, less frequently hospitalized via ER and less symptomatic at S1. A palliative care code was associated with S1 in 25% of pts and with a subsequent MSO/SSR/HAD stay in 60%. Conclusions: This real-life, medico-administrative study, covering all hospitalized patients in France, reveals a higher incidence of iCCA than that previously reported by cancer registries. It also highlights the severity of this disease, the central role of CHG in the management of pts and the expertise of CHU and CLCC for surgery and CT, respectively.

Real-life data on long-term follow-up of patients successfully treated with percutaneous tibial nerve stimulation

2021 ◽  
Vol 73 (2) ◽  
Author(s):  
Daniele BIANCHI ◽  
Valerio IACOVELLI ◽  
Isabella PARISI ◽  
Filomena PETTA ◽  
Gabriele GAZIEV ◽  
...  
Keyword(s):  
Nerve Stimulation ◽  
Tibial Nerve ◽  
Real Life ◽  
Percutaneous Tibial Nerve Stimulation ◽  
Life Data ◽  
Tibial Nerve Stimulation ◽  
Real Life Data ◽  
Long Term Follow Up

scholarly journals P1106Long-term follow-up of cryoballoon versus radiofrequency ablation for paroxysmal atrial fibrillation, real-life data

EP Europace ◽  
2018 ◽  
Vol 20 (suppl_1) ◽  
pp. i205-i205
Author(s):  
A I Molina Ramos ◽  
A Ruiz-Salas ◽  
H Orellana ◽  
C Medina-Palomo ◽  
A Barrera-Cordero ◽  
...  
Keyword(s):  
Atrial Fibrillation ◽  
Radiofrequency Ablation ◽  
Paroxysmal Atrial Fibrillation ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

scholarly journals Serious infections in ANCA-associated vasculitides in the biologic era: real-life data from a multicenter cohort of 162 patients

2021 ◽  
Vol 23 (1) ◽  
Author(s):  
Konstantinos Thomas ◽  
Evangelia Argyriou ◽  
Noemin Kapsala ◽  
Alexandros Panagiotopoulos ◽  
Aglaia Chalkia ◽  
...  
Keyword(s):  
Incidence Rate ◽  
Granulomatosis With Polyangiitis ◽  
Strong Predictor ◽  
Real Life ◽  
Maintenance Phase ◽  
Life Study ◽  
Life Data ◽  
Real Life Data ◽  
Serious Infections

Abstract Background Serious infections (SI) are common in patients with ANCA-associated vasculitides (AAV) like granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA). Real-life data regarding their incidence and predisposing factors—after the introduction of B cell depleting agents—are limited while data quantifying the risk per treatment modality and year of the disease are missing. Here, we aim to describe in details the incidence and the risk factors for SI in a contemporary AAV cohort. Methods Multicenter, observational, retrospective study of AAV patients followed in three tertiary referral centers. Results We included 162 patients with GPA (63%) and MPA (37%), males 51.9%, mean age 60.9 years, ΑΝCA+ 86%, and generalized disease 80%. During follow-up (891.2 patient-years, mean 5.4 years), 67 SI were recorded in 50 patients at an incidence rate of 7.5 per 100 patient-years. The SI incidence rate was higher during induction with cyclophosphamide (CYC) compared to rituximab (RTX, 19.3 vs. 11.3 per 100 patient-years, respectively) while it was lower and comparable between RTX and other regimens (5.52 vs. 4.54 per 100 patient-years, respectively) in the maintenance phase. By multivariate analysis, plasmapheresis (PLEX) and/or dialysis was a strong predictor for an SI during the 1st year after diagnosis (OR = 3.16, 95% CI 1.001–9.96) and throughout the follow-up period (OR = 5.21, 95% CI 1.93–14.07). In contrast, a higher baseline BVAS (OR = 1.11, 95% CI 1.01–1.21) was associated with SI only during the 1st year. Conclusions In this real-life study of patients with AAV, the SI incidence was higher during CYC compared to RTX induction while there was no difference between RTX and other agents used for maintenance therapy. Higher disease activity at baseline and need for PLEX and/or dialysis were independent factors associated with an SI.

scholarly journals Impact of the combined presence of erosions and ACPA on rheumatoid arthritis disease activity over time: results from the METEOR registry

RMD Open ◽  
2019 ◽  
Vol 5 (2) ◽  
pp. e000969
Author(s):  
Sytske Anne Bergstra ◽  
Maura C Couto ◽  
Nimmisha Govind ◽  
Arvind Chopra ◽  
Karen Salomon Escoto ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Disease Activity ◽  
Cox Regression ◽  
Reference Group ◽  
Real Life ◽  
Similar Response ◽  
Life Data ◽  
Real Life Data ◽  
Over Time

ObjectiveTo investigate associations between baseline presence of erosions and/or anti-citrullinated protein antibodies (ACPA) on functional ability, disease activity and treatment survival over time.MethodsReal life data from newly diagnosed rheumatoid arthritis patients were identified in the international METEOR registry. Patients were grouped according to presence/absence of ACPA and/or erosions at baseline. Associations between the presence of ACPA and/or erosions (four groups) with the change of Disease Activity Score (DAS) and Health Assessment Questionnaire (HAQ) over time were assessed using linear mixed models during maximum 6 or maximum 12 months from baseline. Treatment survival was assessed using multiple failure-times Cox regression.ResultsData were included from 701 ACPA‒/erosions‒, 334 ACPA‒/erosions+, 1585 ACPA+/erosions‒ and 1993 ACPA+/erosions+ patients. We found statistically significant differences in DAS and HAQ change over time between the four groups, both after maximum follow-up durations of 6 and of 12 months, but after stratification differences proved small and not clinically meaningful. Patients in the ACPA‒/erosions‒ group were less likely to switch treatment compared with the ACPA+/erosions‒ reference group (p<0.001). The other two ACPA/erosions groups did not differ from the reference group.ConclusionsIn this analysis of worldwide real life data, we found statistically significant, but clinically irrelevant differences in treatment response to initial disease modifying anti-rheumatic drug therapies as measured by DAS and HAQ in ACPA‒/erosions‒, ACPA‒/erosions+, ACPA+/erosions‒ and ACPA+/erosions+ rheumatoid arthritis patients. However, after maximum follow-up durations of 6 and 12 months all groups had a similar response to initial treatment, but with a lower likelihood to switch treatment for ACPA‒/erosions‒ patients during the first year of follow-up.

Sign in / Sign up

Export Citation Format

Share Document